Yupelri and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Yupelri (revefenacin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Budesonide, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Yupelri. It is created by eHealthMe based on reports of 505 people who have side effects when taking Yupelri from the FDA, and is updated regularly.

What is Yupelri?

Yupelri has active ingredients of revefenacin. eHealthMe is studying from 506 Yupelri users. Check the latest studies of Yupelri.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,753 drugs and 2,913 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

On Jul, 14, 2026

505 people reported to have side effects when taking Yupelri.
Among them, 13 people (2.57%) have Hypersensitivity.

Among these 13 people:

How long have people been on Yupelri when they have Hypersensitivity? *

What is the gender of people who have Hypersensitivity when taking Yupelri? *

female: 92.31 %
male: 7.69 %

What is the age of people who have Hypersensitivity when taking Yupelri? *

What are other drugs people take besides Yupelri? *

Vitamin C: 4 people, 30.77%
Budesonide: 4 people, 30.77%
Zyrtec: 3 people, 23.08%
Dexilant: 3 people, 23.08%
Zithromax: 3 people, 23.08%
Fluticasone Propionate: 3 people, 23.08%
Epinephrine: 3 people, 23.08%
Dronabinol: 3 people, 23.08%
Doxycycline: 3 people, 23.08%
Diphenhydramine Hydrochloride: 3 people, 23.08%

What are other side effects people have besides Hypersensitivity? *

Dyspnea (difficult or laboured breathing): 5 people, 38.46%
Pharyngitis (inflammation of the pharynx, causing a sore throat): 3 people, 23.08%
Chest Pain: 3 people, 23.08%
Hypotension (abnormally low blood pressure): 3 people, 23.08%
Viral Infection: 3 people, 23.08%
Bacterial Infection: 3 people, 23.08%
Headache (pain in head): 3 people, 23.08%
Iron Deficiency Anaemia: 3 people, 23.08%
Cough: 3 people, 23.08%
Renal Mass (mass in kidney): 3 people, 23.08%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 3 people, 23.08%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 23.08%
Mycobacterium Avium Complex Infection: 2 people, 15.38%
Obstructive Airways Disorder (a progressive disease that makes it hard to breathe): 1 person, 7.69%
Iron Deficiency Anaemia: 1 person, 7.69%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Yupelri and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yupelri:

Yupelri (506 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

Browse all side effects of Yupelri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,753 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,913 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on revefenacin (the active ingredients of Yupelri) and Yupelri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.